While Brexit provided an expected boost to core earnings for GlaxoSmithKline, it also led to a big write-down—the latest in a series of surprises stemming from Britain’s vote to leave the EU.
from WSJ.com: US Business http://ift.tt/2ay61lX
via IFTTT
No comments:
Post a Comment